Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Methyprylon. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | PTGER2 | P43116 | 8/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 7/20 | 0.35 |
| ▸ | NAAA | Q02083 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 4/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4421342 | 0.82 | TDP1 (0.47) | POLBTDP1FAAHCES1 | |
| Maleic Acid SCHEMBL4564915 | 0.78 | POLB (0.43) | POLBTDP1PTGER2FAAHCES1 | |
| Fumaric Acid SCHEMBL1363596 | 0.78 | POLB (0.43) | POLBTDP1PTGER2FAAHCES1 | |
| SCHEMBL5168860 | 0.69 | POLB (0.45) | POLBTDP1PTGER2PTGER4FAAH | |
| Oxalic Acid SCHEMBL5167291 | 0.67 | POLB (0.44) | POLBTDP1PTGER2PTGER4FAAH | |
| SCHEMBL387695 | 0.67 | HCAR2 (0.43) | POLBTDP1FAAHCES1 | |
| SCHEMBL5167288 | 0.65 | POLB (0.43) | POLBTDP1FAAHCES1 | |
| Oxalic Acid SCHEMBL5165255 | 0.64 | TDP1 (0.41) | POLBTDP1PTGER2PTGER4 | |
| SCHEMBL5168867 | 0.64 | CES1 (0.40) | TDP1FAAHCES1 | |
| SCHEMBL5169422 | 0.64 | POLB (0.47) | POLBTDP1FAAHCES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638551-B2 | Amino alcohol compounds or phosphonic acid derivatives thereof | SANKYO COMPANY, LIMITED (JP) | 2009-12-29 | — | — | US | disclosed |
| US-20070142335-A1 | Amino alcohol compounds or phosphonic acid derivatives thereof | SANKYO COMPANY, LIMITED (JP) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142335-A1 | Amino alcohol compounds or phosphonic acid derivatives thereof | HRH3, C3AR1, HRH4 | POLB 1738/4885TDP1 3799/4885PTGER2 1043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.